Repligen to Acquire BioLife Solutions in $1.5 Billion Deal, Expanding into Cell Therapy Market
Key Insights
Repligen Corp (search) announced a cash-and-stock acquisition of BioLife Solutions (search) valued at approximately $1.5 billion to strengthen its position in the cell therapy manufacturing sector.
BioLife's biopreservation and cell-processing technologies are used in roughly 90% of commercially approved cell therapies, offering Repligen a high-margin recurring revenue stream.
The deal values BioLife at $31 per share, a 6.2% premium, and is expected to close in the fourth quarter of 2026 pending regulatory and shareholder approvals.
Repligen Corp (search) announced on Wednesday it will acquire BioLife Solutions (search) in a cash-and-stock transaction valued at approximately $1.5 billion, a strategic move that significantly expands the drugmaking equipment provider's footprint in the rapidly growing cell therapy market.
Under the terms of the agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share held, valuing the cell therapy tools supplier at $31 per share — a premium of approximately 6.2% to BioLife's last closing price. Shares of BioLife rose about 3% in premarket trading following the announcement.
Strategic Rationale and Market Opportunity
The acquisition gives Repligen access to BioLife's proprietary technology for preserving cells throughout the manufacturing process and supply chain, as well as its portfolio of cell-processing tools and high-margin consumables. According to William Blair analyst Matt Larew, BioLife's products are used in approximately 90% of commercially approved cell therapies, underscoring the company's deep integration into the cell and gene therapy (CGT) ecosystem.
Repligen projects the cell therapy market will grow from less than $7 billion in 2025 to approximately $19 billion by the end of the decade, with commercial revenues expanding at more than 20% annually. The company estimates there are more than 1,100 cell therapies in the global industry pipeline, making it the second most popular modality in biologics after proteins.
Olivier Loeillot, Repligen's president and chief executive, described the acquisition as "a natural next step in the evolution of our strategy," adding that it "further strengthens our position as a leading provider of mission-critical technologies for biologics manufacturing." He noted the deal will also "add a deeply embedded, high-margin consumables business with attractive recurring revenue."
Financial Details and Synergies
The transaction is structured as roughly two-thirds stock and one-third cash. Both companies' boards have unanimously approved the deal, which is expected to close in the fourth quarter of 2026, pending regulatory and shareholder approvals.
Repligen expects the acquisition to be accretive to earnings and to generate at least $20 million in cost savings in the first year after closing, achieved through the elimination of overlapping costs and operational efficiency improvements.
Preliminary second-quarter results indicate BioLife is expecting revenues of $23 million, a 21% increase over the same period in 2025, while Repligen reported first-quarter revenues of $194 million, up 15% year-over-year.
Industry Context
The acquisition follows a broader trend of consolidation in the life sciences tools sector. German drugmaker Merck KGaA announced an $11.3 billion deal to acquire Bio-Techne (search) just one month prior, and larger peer Danaher (search) recently signaled a recovery in demand for bioprocessing products as biotech and pharmaceutical companies increase spending following a multi-year slowdown in research investment and customer inventory drawdowns.
BioLife had already been sharpening its strategic focus prior to the sale. In October 2025, the company divested its evo cold-chain logistics unit for $25.5 million, concentrating its efforts on products tied to cell and gene therapy.
Integration and Operations
Approximately 160 BioLife employees will join Waltham, Massachusetts-headquartered Repligen upon deal closure, supplementing Repligen's current workforce of roughly 2,000. Repligen's existing product lines include equipment and instrumentation for filtration, chromatography, fluid management, and process analytics used in the development and manufacturing of antibodies, antibody-drug conjugates (ADCs), mRNA, plasmid DNA, and viral vectors — a portfolio that will be complemented by BioLife's biopreservation media, cold-chain logistics, and cell processing tools.